8-K: Orchestra BioMed Secures $30M, Initiates Virtue SAB Trial

Orchestra BioMed has entered new strategic agreements with Terumo, securing $30 million in funding and initiating its pivotal U.S. Virtue SAB clinical trial for coronary in-stent restenosis.

Summary

• Orchestra BioMed Holdings, Inc. (OBIO) terminated its prior Distribution Agreement with Terumo and entered into a new Termination and Right of First Refusal (ROFR) Agreement.
• Under the new ROFR Agreement, Terumo will pay Orchestra BioMed a $10 million fee for a right of first refusal on transactions involving Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for coronary artery disease globally.
• Orchestra BioMed retains all development and distribution rights for Virtue SAB in other vascular indications, such as below-the-knee peripheral artery disease.
• Concurrently, Terumo Medical Corporation agreed to invest an additional $20 million in Orchestra BioMed by purchasing 200,000 shares of Series A Convertible Preferred Stock at $100.00 per share.
• The closing of the $20 million preferred stock sale is expected by November 7, 2025.
• Terumo previously made a $30 million non-refundable payment and a $5 million common stock investment under the prior agreement, bringing total payments from Terumo to Orchestra BioMed to $65 million ($30M prior, $10M ROFR fee, $20M preferred stock, $5M common stock).
• Terumo's existing 493,037 shares of common stock are subject to a one-year lockup until October 24, 2026.
• Orchestra BioMed announced the first patient enrollments in the Virtue Trial, its U.S. IDE pivotal trial comparing Virtue SAB to the AGENT paclitaxel-coated balloon for coronary in-stent restenosis (ISR).
• The Virtue Trial aims to enroll 740 patients at up to 75 U.S. centers, with enrollment completion planned for mid-2027.
• Virtue SAB has FDA Breakthrough Device Designation for coronary ISR, coronary small vessel disease, and below-the-knee peripheral artery disease.

Sentiment

Score: 8

Explanation: The company secured substantial new capital, initiated a pivotal clinical trial for a key product with FDA Breakthrough Device Designation, and retained significant commercial rights. These are strong positive developments, although the pivotal trial is still in its early stages with enrollment completion planned for mid-2027, and regulatory approval is not guaranteed.

Positives

• Secured $30 million in new capital from Terumo ($10 million ROFR fee + $20 million preferred stock investment), providing significant resources for pivotal stage programs.
• Retained full rights to Virtue SAB for other vascular indications (e.g., below-the-knee peripheral artery disease), offering future strategic flexibility.
• Initiated patient enrollment in the Virtue Trial, a U.S. pivotal IDE trial for coronary in-stent restenosis (ISR), marking a key development milestone.
• Virtue SAB has FDA Breakthrough Device Designation for multiple indications, including coronary ISR, coronary small vessel disease, and below-the-knee peripheral artery disease.
• The SABRE pilot study demonstrated promising clinical results for Virtue SAB in single-layer coronary ISR, including a 12-month target lesion failure of 2.8% and zero target lesion revascularizations from 12-month through 36-month follow-up.
• The global market opportunity for drug-eluting balloons is estimated to be over $10 billion annually.

Negatives

• The prior distribution agreement with Terumo for Virtue SAB in coronary artery disease was terminated, indicating a change in the original commercialization strategy for this specific indication.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Failure to realize the anticipated benefits of the business combination.
• Risks related to regulatory approval of product candidates.
• Uncertainty regarding the timing of, and the ability to achieve, expected regulatory and business milestones.
• Impact of competitive products and product candidates.
• The company operates in a very competitive and rapidly changing environment, with new risks emerging over time.

Future Outlook

The company anticipates advancing its pivotal stage programs, including the Virtue Trial for Virtue SAB, to key clinical and regulatory milestones. Enrollment for the Virtue Trial is planned for completion by mid-2027, with data expected to support U.S. regulatory approval. The company also aims to seek development and commercialization partnerships for Virtue SAB in various therapeutic indications, leveraging Terumo's right of first refusal for the global coronary market.

Management Comments

• "Our new agreements with Terumo reflect the differentiated value of Virtue SAB for the treatment of atherosclerotic disease in the coronary arteries and provide strategic optionality for both companies." David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed.
• "This new arrangement highlights the strong clinical and commercial potential of Virtue SAB to become a best-in-class therapy in the global coronary market." David Hochman.
• "The $30 million in proceeds from Terumo provides meaningful additional capital resources to advance both of our pivotal stage programs to key clinical and regulatory milestones." David Hochman.
• "We are glad to be aligned with our colleagues at Terumo and are thrilled to have initiated the Virtue Trial evaluating our fundamentally different approach to treating coronary in-stent restenosis." David Hochman.
• "We are very pleased to enter into a new strategic agreement with Orchestra BioMed that reflects the significant potential for Virtue SAB in the treatment of coronary artery disease." Ghada Farah, President of Terumo Interventional Systems.
• "We believe it aligns the objectives of both companies, and we wish Orchestra BioMed great success as they enroll patients in the Virtue Trial." Ghada Farah.

Industry Context

The announcement positions Orchestra BioMed's Virtue SAB as a potentially significant player in the multi-billion dollar annual global market for drug-eluting balloons, particularly for coronary in-stent restenosis (ISR). The Virtue Trial's head-to-head comparison against AGENT paclitaxel-coated balloon, currently the only FDA-approved drug-coated balloon for a coronary indication, highlights the company's ambition to establish Virtue SAB as a best-in-class therapy. The FDA Breakthrough Device Designation further underscores its potential to address unmet needs in coronary and peripheral artery diseases. The strategic agreements with Terumo, a leading global medical device company, provide both capital and a potential commercialization pathway, aligning with broader industry trends of partnerships for innovative medical technologies.

Comparison to Industry Standards

• Virtue SAB's SABRE pilot study demonstrated a 12-month target lesion failure (TLF) of 2.8% and zero target lesion revascularizations (TLR) from 12-month through 36-month follow-up for single-layer coronary ISR. This compares favorably to traditional balloon angioplasty, which has high retreatment rates, and brachytherapy, which is a last-resort treatment due to radiation burden, expense, and limited availability.
• The Virtue Trial is a head-to-head randomized evaluation comparing Virtue SAB to the AGENT paclitaxel-coated balloon, which is currently the only FDA-approved drug-coated balloon (DCB) for a coronary indication. This direct comparison aims to demonstrate non-inferiority in Target Lesion Failure (TLF) at 12 months, a critical benchmark for market acceptance against an established competitor.
• Virtue SAB's design, delivering a liquid dose of SirolimusEFR through a non-coated microporous AngioInfusion Balloon, aims to overcome limitations of existing DCBs by enabling enhanced tissue uptake and extended release of therapeutic levels of sirolimus, exceeding previously published target tissue concentrations of proven drug-eluting stents.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to new capital, advancement of a key product candidate, and strategic optionality. Dilution from preferred stock conversion is a future possibility, but the preferred stock is non-voting.
• Employees: Continued employment and potential growth opportunities as clinical trials advance.
• Customers (Healthcare Providers/Patients): Potential for a new, differentiated treatment option for coronary artery disease and other vascular indications if Virtue SAB gains regulatory approval.
• Creditors: Improved financial stability due to the capital infusion.
• Terumo (Partner): Retains a strategic interest and right of first refusal for a promising product in a key market, while gaining a preferred stock investment in Orchestra BioMed.

Next Steps

• Closing of the $20 million Series A Preferred Stock sale by November 7, 2025.
• Payment of the $10 million ROFR Fee within 10 business days of October 24, 2025.
• Continued enrollment of 740 patients in the Virtue Trial at up to 75 U.S. centers, with completion planned for mid-2027.
• Disclosure of primary endpoint data from the U.S. IDE study for coronary ISR to Terumo or the public, which will trigger the end of the ROFR Period.
• Negotiation of a Virtue Transaction with Terumo if they exercise their ROFR on a third-party proposal.
• Potential pursuit of development and commercialization partnerships for Virtue SAB in various therapeutic indications.
• Filing of a Certificate of Designation of Series A Convertible Preferred Stock with the Secretary of State of Delaware prior to closing.

Key Dates

Recommendation

The filing details a significant capital infusion of $30 million from a strategic partner, Terumo, which substantially strengthens the company's financial position. The initiation of the pivotal Virtue Trial for Virtue SAB, a product with FDA Breakthrough Device Designation and promising pilot study results, marks a critical advancement towards potential market approval in a multi-billion dollar market. The retention of full rights for Virtue SAB in other vascular indications provides additional long-term growth optionality. While regulatory approval and trial success are not guaranteed, these developments significantly de-risk the company's pipeline and provide a clear path forward for a key asset, making it an attractive investment opportunity for long-term growth.

Keywords

Orchestra BioMed, Virtue SAB, Sirolimus AngioInfusion Balloon, Coronary Artery Disease, In-Stent Restenosis, ISR, Drug-Eluting Balloon, DCB, Terumo, Strategic Partnership, Clinical Trial, IDE Study, FDA Breakthrough Device, Preferred Stock, Capital Raise, Medical Device, Cardiovascular